Nu Skin Enterprises Cut to Sell at Zacks

Admin   |   13 July, 2015   |   559   |   3980

Zacks cut shares of Nu Skin Enterprises (NYSE:NUS) from a hold rating to a sell rating in a research note issued to investors on Friday, Market Beat reports.

According to Zacks, “Nu Skin Enterprises, Inc. is a direct selling company that develops and distributes premium-quality, innovative personal care and nutritional products. The company also markets and distributes technology, Internet and telecommunications services and products. The company distributes its products exclusively through a network marketing system. They currently have a network of active distributors located throughout its markets that purchase products for resale to consumers and for personal consumption. “

In other Nu Skin Enterprises news, insider Daniel R. Chard sold 17,500 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $46.67, for a total transaction of $816,725.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

#NuSkin Enterprises (NYSE:NUS) opened at 41.62 on Friday. Nu Skin Enterprises has a 52 week low of $38.12 and a 52 week high of $70.99. The stock’s 50-day moving average is $49.11 and its 200-day moving average is $51.79. The company has a market cap of $2.44 billion and a P/E ratio of 14.81.

Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.72 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.73 by $0.01. The company had revenue of $543.30 million for the quarter, compared to the consensus estimate of $544.70 million. During the same quarter in the prior year, the company posted $1.05 earnings per share. The company’s quarterly revenue was down 20.4% on a year-over-year basis. On average, analysts predict that Nu Skin Enterprises will post $3.69 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. reiterated a hold rating and set a $40.00 price target (down previously from $60.00) on shares of Nu Skin Enterprises in a research note on Friday. Analysts at Citigroup Inc. reiterated a buy rating and set a $55.00 price target (down previously from $56.00) on shares of Nu Skin Enterprises in a research note on Thursday. Analysts at Stifel Nicolaus reiterated a hold rating on shares of Nu Skin Enterprises in a research note on Sunday, May 10th. Finally, analysts at Canaccord Genuity raised their price target on shares of Nu Skin Enterprises from $56.00 to $60.00 and gave the company a hold rating in a research note on Thursday, May 7th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $56.63.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc. is a global direct selling company with operations in 53 markets worldwide. The Company develops and distributes anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands, respectively. The Company introduced Pharmanex nutritional supplements and Nu Skin personal care products under its age LOC anti-aging brand. The Company offers anti-aging personal care products. Products in this category include its ageLOC Galvanic Spa System, its ageLOC Galvanic Body Spa, ageLOC Galvanic Spa Body Shaping Gel and ageLOC Dermatic Effects Body Contouring Lotion and its ageLOC Transformation anti-aging skin care system. The Company markets a variety of products under its Pharmanex brand. LifePak, its line of micronutrient supplements. Other anti-aging nutritional supplements include its ageLOC R2, which is designed to renew and recharge the body.